Gluconat De Calciu Hameln (Calcium Gluconate For Injection)

Gluconat De Calciu Hameln is indicated for several clinical situations where calcium supplementation is required.

• Treatment of hypocalcemia resulting from surgical, traumatic, or metabolic causes.
• Support of calcium levels during parenteral nutrition.
• Cardiac membrane stabilization in patients with hyperkalemia undergoing emergency therapy.
• Management of calcium deficiency associated with vitamin D deficiency or renal disease.
• Adjunct therapy for magnesium toxicity to counteract neuromuscular excitability.

Adverse reactions to calcium gluconate injection are generally infrequent, but they can be categorized by frequency and severity.

Common

• Local irritation or pain at the injection site.
• Mild nausea or vomiting.
• Transient flushing or warmth sensation.
• Mild hypotension when administered rapidly.

Serious

• Severe hypercalcemia with cardiac arrhythmias.
• Tissue necrosis if extravasation occurs.
• Allergic reactions such as urticaria, bronchospasm, or anaphylaxis.

Before administering Gluconat De Calciu Hameln, clinicians should consider several precautionary measures to minimize risk.

• Verify serum calcium levels; avoid use in patients with documented hypercalcemia.
• Use a controlled infusion rate to prevent rapid shifts in calcium concentration.
• Monitor cardiac rhythm and blood pressure during and after infusion.
• Assess for signs of extravasation; discontinue infusion if tissue damage is suspected.
• Use with caution in patients with renal impairment or active kidney stones.
• Pregnancy and lactation status should be evaluated, as safety data are limited.

Calcium gluconate may interact with other medications, influencing their efficacy or safety.

Avoid

• Loop diuretics (e.g., furosemide) that increase calcium excretion.
• Bisphosphonates administered concurrently, which can reduce calcium absorption.
• Calcium‑containing antacids or oral supplements that may cause hypercalcemia.

Use with caution

• Digoxin, as calcium levels can affect its therapeutic window.
• Cardiac glycosides and other drugs that prolong the QT interval.
• Magnesium sulfate, because calcium may counteract its effects.